Stoke Therapeutics, Inc.
STOK
$9.66
$0.303.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.48M | -26.43M | -25.70M | -26.37M | -26.96M |
| Total Depreciation and Amortization | 526.00K | 540.00K | 548.00K | 563.00K | 624.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.94M | 7.52M | 7.70M | 5.94M | 6.56M |
| Change in Net Operating Assets | -20.18M | -3.24M | -30.00K | -4.69M | -875.00K |
| Cash from Operations | -23.19M | -21.62M | -17.48M | -24.57M | -20.65M |
| Capital Expenditure | -42.00K | -103.00K | -46.00K | -12.00K | -229.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 861.00K | -29.90M | -88.23M | 10.00M | 15.00M |
| Cash from Investing | 819.00K | -30.00M | -88.28M | 9.99M | 14.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 568.00K | 8.16M | 120.65M | 1.72M | 7.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 568.00K | 8.16M | 120.65M | 1.72M | 7.34M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.81M | -43.46M | 14.90M | -12.86M | 1.47M |